METHODS FOR CORRECTING CASPASE-9 POINT MUTATIONS
First Claim
1. A method of editing a nucleic acid molecule encoding a Caspase-9 protein, the method comprising contacting the nucleic acid molecule with(a) a fusion protein comprising a nuclease-inactive Cas9 domain and a deaminase domain;
- and(b) an sgRNA targeting the fusion protein of (a) to the Caspase-9-encoding nucleic acid molecule;
wherein the nucleic acid molecule comprises a T>
C and/or an A>
G point mutation in the Caspase-9-encoding nucleic acid molecule as compared to a wild-type Caspase-9-encoding nucleic acid molecule,and wherein the Caspase-9-encoding nucleic acid molecule is contacted with the fusion protein and the sgRNA in an amount effective and under conditions suitable for the deamination the mutant C or G nucleotide base.
2 Assignments
0 Petitions
Accused Products
Abstract
Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant Caspase-9 protein to correct a point mutation associated with a disease or disorder, e.g., with neuroblastoma. The methods provided are useful for correcting a Caspase-9 point mutation within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing enzymes or domains, are provided.
-
Citations
22 Claims
-
1. A method of editing a nucleic acid molecule encoding a Caspase-9 protein, the method comprising contacting the nucleic acid molecule with
(a) a fusion protein comprising a nuclease-inactive Cas9 domain and a deaminase domain; - and
(b) an sgRNA targeting the fusion protein of (a) to the Caspase-9-encoding nucleic acid molecule; wherein the nucleic acid molecule comprises a T>
C and/or an A>
G point mutation in the Caspase-9-encoding nucleic acid molecule as compared to a wild-type Caspase-9-encoding nucleic acid molecule,and wherein the Caspase-9-encoding nucleic acid molecule is contacted with the fusion protein and the sgRNA in an amount effective and under conditions suitable for the deamination the mutant C or G nucleotide base. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
- and
Specification